Mobile website
Archive > Volume 31 Issue 9 > 2024,31(9):907-912. DOI:10.3872/j.issn.1007-385X.2024.09.009 Prev Next
Clinical Research
Clinical efficacy and safety of tumor-specific individualized multi-target DC-CIK therapy for primary liver cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To evaluate the clinical efficacy and safety of tumor-specific individualized multi-target autologous dendritic cells (DC)-cytokine-induced killer cells (CIK) in patients with advanced primary liver cancer (PLC). Methods: The clinical data of 119 patients with advanced PLC who received DC-CIK therapy in the Oncology Department of the General Hospital of the Eastern Theater Command from October 2019 to September 2021 were retrospectively analyzed. Patients were divided into two groups based on the type of antigen used to load DCs during treatment: the pDC-CIK group (n = 21) that used patient-specific polypeptide loaded DCs and the DC-CIK group (n = 98) that used tumor cell lysate-loaded DCs. Clinical data of the two groups before and after treatment were analyzed, including the treatment efficacy and the changes in fetoprotein, lymphocyte subsets, cytokines (IL-2, IFN-γ, TNF-α and IL-6), and adverse reactions. Results: Amont the 119 PLC patients, the objective response rates in both the pDC-CIK and DC-CIK groups were 0%, with disease control rates of 76.1% and 72.4%, respectively (P > 0.05). There was no statistical difference in the levels of CD3+ , CD4+ , CD8+ , CD56+ , CD25+ , CD4+ /CD8+ T lymphocytes between the two groups after treatment (all P > 0.05). However, both groups experienced significantly increased mean levels of IL-2, IFN-γ, TNF-α and IL-6 in peripheral blood after treatment (all P < 0.001). There was no significant difference in the mean levels of IL-2, TNF-α and IL-6 in peripheral blood between the two groups after treatment (all P > 0.05), but the IFN-γ level was significantly higher in the pDC-CIK group than that in the DC-CIK group (P < 0.05). The average survival time of patients in the pDC-CIK group was 59.84 months, which was slightly higher than 46.54 months in the DC-CIK group (P > 0.05). No serious adverse reactions occurred during the treatment. Conclusion: Tumor-specific individualized multi-targeted DC-CIK therapy is safe and effective for PLC patients and can enhance immune function, with a trend toward further benefits compared to tumor cell lysate-loaded DC-CIK therapy.
Keywords:
Project Supported:
Clc Number:
